Eintrag weiter verarbeiten
Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refr...
Gespeichert in:
| Veröffentlicht in: | BMC cancer 18 (2018), 1132 |
|---|---|
| Personen und Körperschaften: | , , , , , , , |
| Titel: | Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)/ Nikolas von Bubnoff, Gabriele Ihorst, Olga Grishina, Nadine Röthling, Hartmut Bertz, Justus Duyster, Jürgen Finke and Robert Zeiser |
| Format: | E-Book Sonderdruck |
| Sprache: | Englisch |
| veröffentlicht: |
London
BioMed Central
2018
Freiburg Albert-Ludwigs-Universität Freiburg 2019 |
| Gesamtaufnahme: |
Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628); 18 (2018), 1132
|
| Schlagwörter: | |
| Quelle: | Verbunddaten SWB Lizenzfreie Online-Ressourcen |
| LEADER | 03449cam a2200709 4500 | ||
|---|---|---|---|
| 001 | 0-1653303379 | ||
| 003 | DE-627 | ||
| 005 | 20190208113759.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190108s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a urn:nbn:de:bsz:25-freidok-171830 |2 urn | |
| 024 | 7 | |a 10.1186/s12885-018-5045-7 |2 doi | |
| 024 | 8 | |a FRUB-opus-17183 |q Opus Nr. | |
| 035 | |a (DE-627)1653303379 | ||
| 035 | |a (DE-576)516008048 | ||
| 035 | |a (DE-599)BSZ516008048 | ||
| 035 | |a (OCoLC)1083940865 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |
| 100 | 1 | |a Bubnoff, Nikolas von |d 1968- |e VerfasserIn |0 (DE-588)121483428 |0 (DE-627)081336810 |0 (DE-576)182602397 |4 aut | |
| 245 | 1 | 0 | |a Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628) |c Nikolas von Bubnoff, Gabriele Ihorst, Olga Grishina, Nadine Röthling, Hartmut Bertz, Justus Duyster, Jürgen Finke and Robert Zeiser |
| 264 | 1 | |a London |b BioMed Central |c 2018 | |
| 264 | 2 | |a Freiburg |b Albert-Ludwigs-Universität Freiburg |c 2019 | |
| 300 | |a 1 Online-Ressource (8 Seiten) |b Diagramme |e Additional file (1 .docx-Datei) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 650 | 0 | 7 | |0 (DE-588)4158009-6 |0 (DE-627)105496340 |0 (DE-576)209838876 |a Transplantat-Wirt-Reaktion |2 gnd |
| 650 | 0 | 7 | |0 (DE-588)4425928-1 |0 (DE-627)216325099 |0 (DE-576)212156357 |a Biomarker |2 gnd |
| 700 | 1 | |a Ihorst, Gabriele |e VerfasserIn |0 (DE-588)1121534643 |0 (DE-627)874338905 |0 (DE-576)480866082 |4 aut | |
| 700 | 1 | |a Grishina, Olga |e VerfasserIn |0 (DE-588)1138451797 |0 (DE-627)896015580 |0 (DE-576)492545022 |4 aut | |
| 700 | 1 | |a Röthling, Nadine |e VerfasserIn |0 (DE-588)1138583979 |0 (DE-627)896078698 |0 (DE-576)492586233 |4 aut | |
| 700 | 1 | |a Bertz, Hartmut |e VerfasserIn |0 (DE-588)1054368686 |0 (DE-627)79138277X |0 (DE-576)410206849 |4 aut | |
| 700 | 1 | |a Duyster, Justus |d 1961- |e VerfasserIn |0 (DE-588)1119158060 |0 (DE-627)87245553X |0 (DE-576)400396130 |4 aut | |
| 700 | 1 | |a Finke, Jürgen |e VerfasserIn |0 (DE-588)1096178028 |0 (DE-627)856561029 |0 (DE-576)467887586 |4 aut | |
| 700 | 1 | |a Zeiser, Robert |d 1975- |e VerfasserIn |0 (DE-588)12346000X |0 (DE-627)082568081 |0 (DE-576)293718016 |4 aut | |
| 773 | 0 | 8 | |i Sonderdruck aus |t BMC cancer |g 18 (2018), 1132 |x 1471-2407 |
| 856 | 4 | 0 | |u http://nbn-resolving.de/urn:nbn:de:bsz:25-freidok-171830 |q application/pdf |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://nbn-resolving.de/urn:nbn:de:bsz:25-freidok-171830 |q application/x-zip-compressed |x Resolving-System |z kostenfrei |3 Volltext |
| 935 | |c so | ||
| 951 | |a BO | ||
| 856 | 4 | 0 | |u http://nbn-resolving.de/urn:nbn:de:bsz:25-freidok-171830 |9 LFER |
| 852 | |a LFER |z 2019-01-10T00:00:00Z | ||
| 970 | |c OD | ||
| 971 | |c EBOOK | ||
| 972 | |c EBOOK | ||
| 973 | |c EB | ||
| 935 | |a lfer | ||
| 900 | |a Duyster, Justus G. | ||
| 900 | |a Bubnoff, Nikolas Chr. C. von | ||
| 900 | |a Bubnoff, Nikolas C. C. von | ||
| 950 | |a Graft-versus-host-reaction | ||
| 950 | |a Graft versus host reaction | ||
| 950 | |a Graft-versus-host-disease | ||
| 950 | |a Gvhd | ||
| 950 | |a Immunreaktion | ||
| 950 | |a Biochemischer Marker | ||
| 950 | |a Biologischer Marker | ||
| 950 | |a Marker | ||
| 951 | |b XA-DE | ||
| 980 | |a 1653303379 |b 0 |k 1653303379 |o 516008048 |u 2023-06-21 |c lfer | ||
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Ruxolitinib+in+GvHD+%28RIG%29+study%3A+a+multicenter%2C+randomized+phase+2+trial+to+determine+the+response+rate+of+ruxolitinib+and+best+available+treatment+%28BAT%29+versus+BAT+in+steroid-refractory+acute+graft-versus-host+disease+%28aGvHD%29+%28NCT02396628%29&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rft.creator=Bubnoff%2C+Nikolas+von&rft.pub=BioMed+Central&rft.format=Journal&rft.language=English&rft.issn=1471-2407 |
|---|
| _version_ | 1769287931097251840 |
|---|---|
| access_facet | Electronic Resources |
| author | Bubnoff, Nikolas von, Ihorst, Gabriele, Grishina, Olga, Röthling, Nadine, Bertz, Hartmut, Duyster, Justus, Finke, Jürgen, Zeiser, Robert |
| author_facet | Bubnoff, Nikolas von, Ihorst, Gabriele, Grishina, Olga, Röthling, Nadine, Bertz, Hartmut, Duyster, Justus, Finke, Jürgen, Zeiser, Robert |
| author_role | aut, aut, aut, aut, aut, aut, aut, aut |
| author_sort | Bubnoff, Nikolas von 1968- |
| author_variant | n v b nv nvb, g i gi, o g og, n r nr, h b hb, j d jd, j f jf, r z rz |
| callnumber-sort | |
| collection | lfer |
| container_reference | 18 (2018), 1132 |
| container_title | BMC cancer |
| ctrlnum | (DE-627)1653303379, (DE-576)516008048, (DE-599)BSZ516008048, (OCoLC)1083940865 |
| dewey-full | 610 |
| dewey-hundreds | 600 - Technology |
| dewey-ones | 610 - Medicine & health |
| dewey-raw | 610 |
| dewey-search | 610 |
| dewey-sort | 3610 |
| dewey-tens | 610 - Medicine & health |
| doi_str_mv | 10.1186/s12885-018-5045-7 |
| facet_avail | Online, Free |
| finc_class_facet | Technik, Medizin |
| finc_id_str | 0021448225 |
| fincclass_txtF_mv | medicine |
| format | eBook, SpecialPrint |
| format_access_txtF_mv | Book, E-Book |
| format_de105 | Ebook |
| format_de14 | Book, E-Book |
| format_de15 | Book, E-Book |
| format_del152 | Buch |
| format_detail_txtF_mv | text-online-monograph-independent |
| format_dezi4 | e-Book |
| format_finc | Book, E-Book |
| format_legacy | ElectronicBook |
| format_legacy_nrw | Book, E-Book |
| format_nrw | Book, E-Book |
| format_strict_txtF_mv | E-Book |
| geogr_code | not assigned |
| geogr_code_person | Germany |
| hierarchy_parent_id | |
| hierarchy_parent_title | BMC cancer |
| hierarchy_sequence | 18 (2018), 1132 |
| hierarchy_top_id | |
| hierarchy_top_title | BMC cancer |
| id | 0-1653303379 |
| illustrated | Not Illustrated |
| imprint | London, BioMed Central, 2018 |
| imprint_str_mv | London: BioMed Central, 2018 |
| institution | DE-D117, DE-105, LFER, DE-Ch1, DE-15, DE-14, DE-Zwi2 |
| is_hierarchy_id | |
| is_hierarchy_title | |
| isil_str_mv | LFER |
| issn | 1471-2407 |
| kxp_id_str | 1653303379 |
| language | English |
| last_indexed | 2023-06-21T05:14:13.131Z |
| local_heading_facet_dezwi2 | Transplantat-Wirt-Reaktion, Biomarker |
| marc024a_ct_mv | urn:nbn:de:bsz:25-freidok-171830, 10.1186/s12885-018-5045-7, FRUB-opus-17183 |
| match_str | bubnoff2018ruxolitinibingvhdrigstudyamulticenterrandomizedphase2trialtodeterminetheresponserateofruxolitinibandbestavailabletreatmentbatversusbatinsteroidrefractoryacutegraftversushostdiseaseagvhdnct02396628 |
| mega_collection | Verbunddaten SWB, Lizenzfreie Online-Ressourcen |
| misc_de105 | EBOOK |
| names_id_str_mv | (DE-588)121483428, (DE-627)081336810, (DE-576)182602397, (DE-588)1121534643, (DE-627)874338905, (DE-576)480866082, (DE-588)1138451797, (DE-627)896015580, (DE-576)492545022, (DE-588)1138583979, (DE-627)896078698, (DE-576)492586233, (DE-588)1054368686, (DE-627)79138277X, (DE-576)410206849, (DE-588)1119158060, (DE-627)87245553X, (DE-576)400396130, (DE-588)1096178028, (DE-627)856561029, (DE-576)467887586, (DE-588)12346000X, (DE-627)082568081, (DE-576)293718016 |
| oclc_num | 1083940865 |
| physical | 1 Online-Ressource (8 Seiten); Diagramme; Additional file (1 .docx-Datei) |
| publishDate | 2018, , 2019 |
| publishDateSort | 2018 |
| publishPlace | London, ; Freiburg |
| publisher | BioMed Central, : Albert-Ludwigs-Universität Freiburg |
| record_format | marcfinc |
| record_id | 516008048 |
| recordtype | marcfinc |
| rvk_facet | No subject assigned |
| source_id | 0 |
| spelling | Bubnoff, Nikolas von 1968- VerfasserIn (DE-588)121483428 (DE-627)081336810 (DE-576)182602397 aut, Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628) Nikolas von Bubnoff, Gabriele Ihorst, Olga Grishina, Nadine Röthling, Hartmut Bertz, Justus Duyster, Jürgen Finke and Robert Zeiser, London BioMed Central 2018, Freiburg Albert-Ludwigs-Universität Freiburg 2019, 1 Online-Ressource (8 Seiten) Diagramme Additional file (1 .docx-Datei), Text txt rdacontent, Computermedien c rdamedia, Online-Ressource cr rdacarrier, (DE-588)4158009-6 (DE-627)105496340 (DE-576)209838876 Transplantat-Wirt-Reaktion gnd, (DE-588)4425928-1 (DE-627)216325099 (DE-576)212156357 Biomarker gnd, Ihorst, Gabriele VerfasserIn (DE-588)1121534643 (DE-627)874338905 (DE-576)480866082 aut, Grishina, Olga VerfasserIn (DE-588)1138451797 (DE-627)896015580 (DE-576)492545022 aut, Röthling, Nadine VerfasserIn (DE-588)1138583979 (DE-627)896078698 (DE-576)492586233 aut, Bertz, Hartmut VerfasserIn (DE-588)1054368686 (DE-627)79138277X (DE-576)410206849 aut, Duyster, Justus 1961- VerfasserIn (DE-588)1119158060 (DE-627)87245553X (DE-576)400396130 aut, Finke, Jürgen VerfasserIn (DE-588)1096178028 (DE-627)856561029 (DE-576)467887586 aut, Zeiser, Robert 1975- VerfasserIn (DE-588)12346000X (DE-627)082568081 (DE-576)293718016 aut, Sonderdruck aus BMC cancer 18 (2018), 1132 1471-2407, http://nbn-resolving.de/urn:nbn:de:bsz:25-freidok-171830 application/pdf Resolving-System kostenfrei Volltext, http://nbn-resolving.de/urn:nbn:de:bsz:25-freidok-171830 application/x-zip-compressed Resolving-System kostenfrei Volltext, http://nbn-resolving.de/urn:nbn:de:bsz:25-freidok-171830 LFER, LFER 2019-01-10T00:00:00Z |
| spellingShingle | Bubnoff, Nikolas von, Ihorst, Gabriele, Grishina, Olga, Röthling, Nadine, Bertz, Hartmut, Duyster, Justus, Finke, Jürgen, Zeiser, Robert, Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628), Transplantat-Wirt-Reaktion, Biomarker |
| swb_id_str | 516008048 |
| title | Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628) |
| title_auth | Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628) |
| title_full | Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628) Nikolas von Bubnoff, Gabriele Ihorst, Olga Grishina, Nadine Röthling, Hartmut Bertz, Justus Duyster, Jürgen Finke and Robert Zeiser |
| title_fullStr | Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628) Nikolas von Bubnoff, Gabriele Ihorst, Olga Grishina, Nadine Röthling, Hartmut Bertz, Justus Duyster, Jürgen Finke and Robert Zeiser |
| title_full_unstemmed | Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628) Nikolas von Bubnoff, Gabriele Ihorst, Olga Grishina, Nadine Röthling, Hartmut Bertz, Justus Duyster, Jürgen Finke and Robert Zeiser |
| title_in_hierarchy | |
| title_short | Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628) |
| title_sort | ruxolitinib in gvhd rig study a multicenter randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment bat versus bat in steroid refractory acute graft versus host disease agvhd nct02396628 |
| topic | Transplantat-Wirt-Reaktion, Biomarker |
| topic_facet | Transplantat-Wirt-Reaktion, Biomarker |
| url | http://nbn-resolving.de/urn:nbn:de:bsz:25-freidok-171830 |
| urn | urn:nbn:de:bsz:25-freidok-171830 |